The IPO was priced at $20 a share--above the midpoint of the range--and rose when trading began on Friday.
TriVascular Techologies is setting the terms for its planned IPO, and the California maker of stent grafts to treat abdominal aortic aneurysms aims for a fairly robust debut.
Ariosa Diagnostics filed plans for an IPO worth as much as $69 million. The company said it will use the money, in part, to heighten commercialization efforts for its Harmony prenatal genetic test.
The first two days of trading passed uneventfully, with Circassia's stock fluctuating around the 310 pence ($5.20) per share price it commanded in the IPO to close on Wednesday at 309 pence.
California's TriVascular Technologies is betting it can broaden the reach of its FDA-approved stent grafts to treat abdominal aortic aneurysms and has filed plans to raise up to $100 million in an IPO to help accomplish its goal.
Lombard Medical is disclosing IPO details following its initial announcement in January. The U.K. maker of an aortic repair device said it plans to raise up to $80 million, and will trade on the Nasdaq under the symbol "EVAR," according to a regulatory filing.
Quotient, a U.K. company focused on blood transfusion diagnostics, unveiled plans for an initial public offering that would raise as much as $75 million. The move continues a steady trickle of IPO movement among testing companies that began late last fall.
Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.
It is months since the chatter around Chinese sequencing giant BGI's initial public offering advanced from "will it happen?" to "when, where and how much?" Now Bloomberg has some answers. A $400 million IPO in Hong Kong is reportedly penciled in for the fourth quarter.
European financial markets have largely missed out on the biotech IPO boom, with the few local companies to go public traveling to the U.S. to file their papers. Now British vaccine developer Circassia is to test investor appetite in the United Kingdom with a bumper $285 million IPO.